ESLA · XBRL financial data

Estrella Immunopharma financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ESLA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2024†Jun 30, 2024	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	—	—	4,109	—	10,249
General and administrative	—	—	3,201	—	2,814
Total operating expenses	—	—	7,310	—	13,063
Operating income (loss)	(249)	(1,570)	(7,310)	—	(13,063)
Interest income	1	654	—	—	—
Income tax expense (benefit)	0	81	2	—	1
Net income (loss)	(248)	(996)	(7,312)	—	(13,064)
Earnings per share, basic USD per share	—	—	(0.27)	—	(0.35)
Earnings per share, diluted USD per share	—	—	(0.27)	—	(0.35)
Weighted average shares, basic thousands of shares	1,179	—	27,104	—	36,821
Weighted average shares, diluted thousands of shares	1,179	—	27,104	—	36,821

† Share count changed about 16x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ESLA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2024†Jun 30, 2024	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	479	41	4,165	917	1,384
Prepaid and other current assets	—	—	289	724	293
Total current assets	616	52	4,454	1,641	1,677
Total assets	45,803	9,724	4,454	3,141	3,177
Total current liabilities	73	1,073	181	2,997	13,543
Total deposits	—	—	1,500	1,500	1,500
Total liabilities	1,624	2,653	181	2,997	13,543
Accumulated deficit	(1,006)	(2,256)	(19,500)	(23,927)	(36,991)
Total stockholders' equity	(1,006)	(2,256)	4,273	144	(10,366)
Total liabilities and equity	45,803	9,724	4,454	3,141	3,177
Common shares outstanding (cover page) thousands of shares	5,850	2,330	36,191	36,166	42,665

† Share count changed about 16x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ESLA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2024†Jun 30, 2024	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(248)	(996)	(7,312)	—	(13,064)
Stock-based compensation	—	—	1,195	—	619
Net cash from operating activities	(316)	(1,044)	(16,068)	—	(1,786)
Net cash from investing activities	(45,186)	36,170	4,961	—	—
Proceeds from issuing common stock	25	—	—	—	2,400
Proceeds from issuing equity	44,300	—	—	—	—
Net cash from financing activities	45,981	(35,564)	12,794	—	2,253
Net change in cash	479	(438)	—	—	—

† Share count changed about 16x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Estrella Immunopharma	100	not reported	(1,781)*	43.5M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Fibrogen	50,644	(1,474)	(3,991)*	4.0M	22.9 quarters	Q2 FY26 10-QJun 30, 2026
Armata Pharmaceuticals	23,952	not reported	(8,666)*	37.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Imunon	6,864	not reported	(3,025)*	5.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Lunai Bioworks	1,714	31*	(1,841)*	5.0M	0.9 quarters	Q4 FY26 10-KJun 30, 2026
Dare Bioscience	12,618	188	(6,775)*	15.3M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Aptose Biosciences	1,020	not reported	(5,841)	2.6M	0.2 quarters	Q1 FY26 10-QMar 31, 2026
CEL-SCI	6,527	not reported	(4,031)*	17.6M	1.6 quarters	Q3 FY26 10-QJun 30, 2026
Ovid Therapeutics	11,327	733	(17,594)*	195.3M	6.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.